BR0012205A - Cristais de dinucleótido - Google Patents
Cristais de dinucleótidoInfo
- Publication number
- BR0012205A BR0012205A BR0012205-0A BR0012205A BR0012205A BR 0012205 A BR0012205 A BR 0012205A BR 0012205 A BR0012205 A BR 0012205A BR 0012205 A BR0012205 A BR 0012205A
- Authority
- BR
- Brazil
- Prior art keywords
- crystals
- dcp4u
- present
- ump
- deoxycytidine
- Prior art date
Links
- 239000013078 crystal Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 abstract 4
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 abstract 3
- DJJCXFVJDGTHFX-ZAKLUEHWSA-N uridine-5'-monophosphate Chemical compound O[C@@H]1[C@@H](O)[C@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-ZAKLUEHWSA-N 0.000 abstract 3
- NCMVOABPESMRCP-SHYZEUOFSA-N 2'-deoxycytosine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 NCMVOABPESMRCP-SHYZEUOFSA-N 0.000 abstract 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 abstract 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000007858 starting material Substances 0.000 abstract 2
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 abstract 1
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 abstract 1
- YDHWWBZFRZWVHO-UHFFFAOYSA-H [oxido-[oxido(phosphonatooxy)phosphoryl]oxyphosphoryl] phosphate Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O YDHWWBZFRZWVHO-UHFFFAOYSA-H 0.000 abstract 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 235000010290 biphenyl Nutrition 0.000 abstract 1
- 239000004305 biphenyl Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- -1 diphenyl phosphochloride Chemical compound 0.000 abstract 1
- 235000011180 diphosphates Nutrition 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 abstract 1
- 229940045145 uridine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"CRISTAIS DE DINUCLEóTIDO". A presente invenção refere-se a cristais de P^ 1^ - ( 2' desoxicitidino 5'- ) p^ 4^ ( uridino 5' - )tetrafosfato ( dCP4U ) ou um de seus sais e a um processo de produção dos cristais. A presente invenção também fornece um processo de produção de dCP4U que envolve a reação de 5' -monofosfato de uridina ( UMP ), 5' -monofosfato de 2' -desoxicitidina ( dCMP ), fosfocloridrato de difenila ( DPC ) e pirofosfato ( PPi ). Os cristais de dCP4U obtidos através do processo de acordo com a presente invenção apresentam alta pureza, alta estabilidade e nenhuma higroscopia, em comparação com um produto seco por congelamento, servindo, portanto, de material inicial útil para a preparação de um produto farmacêutico. O processo de produção de dCP4U de acordo com a presente invenção permite a utilização de UMP de baixo custo como material inicial e gera alto rendimento. Assim, o processo é apropriado para síntese em larga escala de dCP4U.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18495099 | 1999-06-30 | ||
| PCT/JP2000/004336 WO2001002416A1 (fr) | 1999-06-30 | 2000-06-30 | Cristaux dinucleotidiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0012205A true BR0012205A (pt) | 2002-05-28 |
Family
ID=16162200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0012205-0A BR0012205A (pt) | 1999-06-30 | 2000-06-30 | Cristais de dinucleótido |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6617444B1 (pt) |
| EP (2) | EP1191032B1 (pt) |
| JP (1) | JP3421666B2 (pt) |
| KR (1) | KR100593723B1 (pt) |
| CN (1) | CN1144811C (pt) |
| AT (2) | ATE300551T1 (pt) |
| AU (1) | AU767136B2 (pt) |
| BR (1) | BR0012205A (pt) |
| CA (1) | CA2376860C (pt) |
| CZ (1) | CZ303172B6 (pt) |
| DE (2) | DE60006814T2 (pt) |
| EA (1) | EA004707B1 (pt) |
| ES (2) | ES2211566T3 (pt) |
| HU (1) | HU229225B1 (pt) |
| IL (1) | IL147163A (pt) |
| MX (1) | MXPA02000035A (pt) |
| NO (1) | NO321169B1 (pt) |
| NZ (1) | NZ516301A (pt) |
| PL (2) | PL202200B1 (pt) |
| SK (1) | SK284178B6 (pt) |
| WO (1) | WO2001002416A1 (pt) |
| ZA (1) | ZA200110468B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223744B2 (en) | 1997-02-10 | 2007-05-29 | Inspire Pharmaceuticals, Inc. | Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof |
| US7078391B2 (en) | 1997-02-10 | 2006-07-18 | Inspire Pharmaceuticals, Inc. | Method of treating edematous retinal disorders |
| US6818629B2 (en) | 1997-02-10 | 2004-11-16 | Inspire Pharmaceuticals, Inc. | Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate |
| US6548658B2 (en) * | 1997-07-25 | 2003-04-15 | Inspire Pharmaceuticals, Inc. | Di-(uridine 5′)-tetraphosphate and salts thereof |
| US6872710B2 (en) | 1997-07-25 | 2005-03-29 | Inspire Pharmaceuticals, Inc. | Di(uridine 5′)-tetraphosphate and salts thereof |
| SK284178B6 (sk) * | 1999-06-30 | 2004-10-05 | Yamasa Corporation | Kryštalická forma P1-(2'-deoxycytidín-5'-)P4-(uridín-5'- )tetrafosfátu a spôsob ich prípravy |
| US6867199B2 (en) | 2000-08-21 | 2005-03-15 | Inspire Pharmaceuticals, Inc. | Dinucleoside polyphosphate compositions and their therapeutic use |
| US7161029B2 (en) * | 2003-12-17 | 2007-01-09 | Ajinomoto Co., Inc. | DiL-lysine monosulfate trihydrate crystal and method of making |
| CN100363376C (zh) * | 2006-06-12 | 2008-01-23 | 南京工业大学 | 一种5’-核苷三磷酸钠盐的结晶方法 |
| JPWO2017002827A1 (ja) * | 2015-06-29 | 2018-04-26 | ヤマサ醤油株式会社 | Ｐ１，ｐ４−ビス（５’−ウリジル）テトラホスフェート結晶の保管方法 |
| CN109843901B (zh) * | 2016-10-25 | 2022-04-26 | Yamasa 酱油株式会社 | P1,p4-二(尿苷5’-)四磷酸的纯化方法 |
| CN111253456B (zh) * | 2020-03-13 | 2021-05-11 | 广东先强药业有限公司 | 一种地纽福索钠的制备方法 |
| CN111704637A (zh) * | 2020-06-28 | 2020-09-25 | 南京工业大学 | 一种采用膜蒸馏结晶精制核苷酸的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07242685A (ja) * | 1994-01-12 | 1995-09-19 | Unitika Ltd | ジアデノシン四リン酸水和物の製造方法 |
| US5837861A (en) * | 1997-02-10 | 1998-11-17 | Inspire Pharmaceuticals, Inc. | Dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency |
| US5900407A (en) * | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
| CN1262556C (zh) * | 1997-02-06 | 2006-07-05 | 印斯拜尔药品股份有限公司 | 特定的二核苷酸和它们作为粘膜纤毛清除和纤毛颤动频率调节剂的应用 |
| US6596725B2 (en) * | 1997-02-10 | 2003-07-22 | Inspire Pharmaceuticals, Inc. | Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema |
| TW593331B (en) * | 1997-07-25 | 2004-06-21 | Inspire Pharmaceuticals Inc | Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof |
| DK1012154T3 (da) * | 1997-07-25 | 2004-07-26 | Inspire Pharmaceuticals Inc | Salte af di(uridin-5'-tetraphosphat), fremgangsmåde til fremstilling og anvendelser deraf |
| WO1999061012A2 (en) * | 1998-05-22 | 1999-12-02 | Inspire Pharmaceuticals, Inc. | Therapeutic dinucleotide and derivatives |
| SK283729B6 (sk) * | 1998-10-02 | 2003-12-02 | Yamasa Corporation | Kryštály P1, P4-di(uridín-5')-tetrafosfátu alebo kryštály jeho soli, spôsob ich výroby, kryštály tetrasodnej soli P1, P4-di(uridín-5')-tetrafosfátu a kryštály jej hydrátov |
| WO2000039145A1 (en) * | 1998-12-23 | 2000-07-06 | The University Of North Carolina At Chapel Hill | Targeted gene transfer using g protein coupled receptors |
| SK284178B6 (sk) * | 1999-06-30 | 2004-10-05 | Yamasa Corporation | Kryštalická forma P1-(2'-deoxycytidín-5'-)P4-(uridín-5'- )tetrafosfátu a spôsob ich prípravy |
-
2000
- 2000-06-30 SK SK1870-2001A patent/SK284178B6/sk not_active IP Right Cessation
- 2000-06-30 MX MXPA02000035A patent/MXPA02000035A/es active IP Right Grant
- 2000-06-30 WO PCT/JP2000/004336 patent/WO2001002416A1/ja not_active Application Discontinuation
- 2000-06-30 AT AT03018399T patent/ATE300551T1/de not_active IP Right Cessation
- 2000-06-30 US US09/700,728 patent/US6617444B1/en not_active Expired - Lifetime
- 2000-06-30 PL PL352363A patent/PL202200B1/pl unknown
- 2000-06-30 ES ES00942412T patent/ES2211566T3/es not_active Expired - Lifetime
- 2000-06-30 NZ NZ516301A patent/NZ516301A/en not_active IP Right Cessation
- 2000-06-30 DE DE60006814T patent/DE60006814T2/de not_active Expired - Lifetime
- 2000-06-30 JP JP2001507852A patent/JP3421666B2/ja not_active Expired - Fee Related
- 2000-06-30 EP EP00942412A patent/EP1191032B1/en not_active Expired - Lifetime
- 2000-06-30 BR BR0012205-0A patent/BR0012205A/pt not_active Application Discontinuation
- 2000-06-30 CZ CZ20014502A patent/CZ303172B6/cs not_active IP Right Cessation
- 2000-06-30 CA CA002376860A patent/CA2376860C/en not_active Expired - Fee Related
- 2000-06-30 IL IL14716300A patent/IL147163A/xx not_active IP Right Cessation
- 2000-06-30 PL PL384307A patent/PL202176B1/pl unknown
- 2000-06-30 CN CNB008097356A patent/CN1144811C/zh not_active Expired - Fee Related
- 2000-06-30 EP EP03018399A patent/EP1362862B1/en not_active Expired - Lifetime
- 2000-06-30 AT AT00942412T patent/ATE255123T1/de not_active IP Right Cessation
- 2000-06-30 DE DE60021629T patent/DE60021629T2/de not_active Expired - Lifetime
- 2000-06-30 ES ES03018399T patent/ES2245431T3/es not_active Expired - Lifetime
- 2000-06-30 EA EA200200109A patent/EA004707B1/ru not_active IP Right Cessation
- 2000-06-30 KR KR1020017016184A patent/KR100593723B1/ko not_active IP Right Cessation
- 2000-06-30 AU AU57067/00A patent/AU767136B2/en not_active Ceased
- 2000-06-30 HU HU0201531A patent/HU229225B1/hu not_active IP Right Cessation
-
2001
- 2001-12-20 ZA ZA200110468A patent/ZA200110468B/en unknown
- 2001-12-27 NO NO20016381A patent/NO321169B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0012205A (pt) | Cristais de dinucleótido | |
| Nomura et al. | Nucleosides and nucleotides. 185. Synthesis and biological activities of 4 ‘α-C-Branched-Chain sugar pyrimidine nucleosides | |
| US4963662A (en) | Fluorinated nucleosides and method for treating retrovirus infections therewith | |
| CN100560073C (zh) | 用于治疗病毒感染的n4-酰基胞嘧啶核苷 | |
| Mehellou et al. | Phosphoramidates of 2′-β-d-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism | |
| EP2955190A2 (en) | Chemical compounds | |
| Gillerman et al. | An improved one-pot synthesis of nucleoside 5′-triphosphate analogues | |
| HU193893B (en) | Process for preparing antiviral 2-deoxy-2,2-difluoropentozyl nucleoside derivatives | |
| EP1150988A1 (en) | Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1r, cis)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol as antiviral agents | |
| BR0011708A (pt) | Derivados de indol e seu uso para o tratamento de osteoporose dentre outras aplicações | |
| JPS5953499A (ja) | デスオキシウリジン誘導体、その製造法および医薬 | |
| WO1998038202A1 (en) | Antiviral phosphonate prodrugs of nucleosides and nucleoside analogues | |
| Sun et al. | 4, 5-Dicyanoimidazole-promoted synthesis of dinucleoside polyphosphates and their analogs | |
| BR9914453A (pt) | Cristal de tetrafosfato de diuridina ou seu sal, método de sua preparação e método de produção do mencionado composto | |
| Ren et al. | Versatile synthesis and biological evaluation of novel 3’-fluorinated purine nucleosides | |
| CN102827902A (zh) | 一种化学-生物酶法组合制备2′-脱氧尿苷的方法 | |
| CA2008806A1 (en) | Process for the enzymatic synthesis of nucleosides | |
| Nicotra et al. | C-glycosides through the Wittig-cyclization procedure: Observations on the influence of the nature of the substrate. | |
| US5153180A (en) | Fluorinated nucleosides and process for treating retrovirus infections therewith | |
| Eckstein et al. | Stereochemistry of the transesterification step of pancreatic ribonuclease | |
| Millo et al. | Simple Synthesis of P1P2-Diadenosine 5′-Pyrophosphate | |
| CN106317147B (zh) | 核苷类化合物及其制备方法 | |
| KR100325682B1 (ko) | 2',3'-디디하이드로-2',3'-디데옥시시티딘 유도체의 제조방법 | |
| Dias et al. | Design, synthesis and In Vitro evaluation on glucosamine-6P synthase of aromatic analogs of 2-Aminohexitols-6P | |
| Mohamady et al. | Rapid and efficient synthesis of nucleoside polyphosphates and their conjugates using sulfonyl imidazolium salts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08E | Application fees: payment of additional fee required [chapter 8.5 patent gazette] |
Free format text: CONFORME RESOLUCAO 124/06, O DEPOSITANTE DEVERA COMPLEMENTAR A RETRIBUICAO DA 7A ANUIDADE, REFERENTE A GUIA DE RECOLHIMENTO 22060250257-5. |
|
| B25A | Requested transfer of rights approved |
Owner name: INSPIRE PHARMACEUTICALS, INC. (US) Free format text: TRANSFERIDO DE: YAMASA CORPORATION |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME CORP. (US) Free format text: TRANSFERIDO DE: INSPIRE PHARMACEUTICALS, INC. |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |